Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2026-03-26 Annual Report
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Annual Report Classification · 95% confidence The document is an 'Annual Results Announcement' for Zai Lab Limited for the year ended December 31, 2025. It contains comprehensive financial highlights, a full independent auditor's report by KPMG, and detailed consolidated balance sheets. While it is titled an 'Announcement', it provides the full audited financial statements and performance data for the fiscal year, which aligns with the definition of an Annual Report (10-K) in the context of global corporate filings, as it serves as the primary vehicle for reporting annual financial results. FY 2025
2026-03-26 English
NOTICE OF BOARD ACTION
Report Publication Announcement Classification · 95% confidence The document is a short announcement (2326 characters) titled 'NOTICE OF BOARD ACTION'. It informs shareholders that the board will meet to consider and approve the annual results for the year ended December 31, 2025, in accordance with HK Listing Rules, and mentions that the 10-K was already filed. Since this is an announcement regarding the timing and publication of upcoming results rather than the financial report itself, it falls under the Report Publication Announcement (RPA) category.
2026-03-16 English
GRANT OF SHARE OPTIONS, RESTRICTED SHARE UNITS AND PERFORMANCE SHARE UNITS
Remuneration Information Classification · 95% confidence The document is an official announcement from Zai Lab Limited regarding the grant of share options, restricted share units (RSUs), and performance share units (PSUs) to its CEO, Dr. Samantha Du. It details the number of shares, exercise prices, vesting periods, and compliance with the Hong Kong Stock Exchange Listing Rules. This type of disclosure, which details equity-based compensation and incentive plans for directors/executives, falls under the category of Remuneration Information.
2026-03-13 English
GRANT OF SHARE OPTIONS, RESTRICTED SHARE UNITS AND PERFORMANCE SHARE UNITS
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Zai Lab Limited regarding the grant of share options, restricted share units (RSUs), and performance share units (PSUs) to senior managers under their 2024 Equity Incentive Plan. This type of disclosure, which details changes in capital structure and equity-based compensation, is classified as a 'Share Issue/Capital Change' (SHA) announcement under the provided definitions, as it relates to the issuance of underlying shares and equity incentives.
2026-03-09 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zai Lab Limited regarding the grant of share options and restricted share units to employees under their 2024 Equity Incentive Plan. This type of disclosure is a standard regulatory requirement for listed companies in Hong Kong (HKEX) to inform the market about changes in capital structure or equity-based compensation. While it involves shares, it is not a 'Transaction in Own Shares' (buyback) nor a 'Director's Dealing' (as the grantees are explicitly stated not to be directors or senior managers). It falls under the category of general regulatory filings required by the Listing Rules for equity incentive grants.
2026-03-05 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 95% confidence The document is titled 'LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS' and provides a breakdown of the board members, their independent status, and their committee memberships. This type of disclosure is a standard corporate governance filing detailing the composition of the board and its committees, which falls under the 'Governance Information' category.
2026-03-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.